Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says

12:07 PM EST, 11/05/2026 (MT Newswires) -- Acadia Pharmaceuticals (ACAD) reported Q3 results underpinned by continued Daybue growth and steady Nuplazid sales, RBC Capital Markets said in a note Thursday. Acadia reported Wednesday Q3 revenue of $342.3 million, versus the FactSet estimate of $332.6 million. The beat by Daybue, the treatment for Rett syndrome in adults and pediatric patients, was driven by continued patient uptake, with further US growth expected as the company reaches more existing patients and those who previously discontinued treatment, the analysts said. This suggests the drug's improved profile may be resonating with patients. European launch efforts are also underway and could provide an additional boost to sales, the analysts said, adding that sales of the antipsychotic medication Nuplazid remained steady. Acadia reiterated its peak 2028 sales estimate of $1 billion for Nuplazid and $700 million for Daybue. The company also has several key clinical trial readouts expected in 2027, and while these trials are "higher-risk," the company's valuation of less than $4 billion does not fully reflect its existing commercial franchises, which have estimated combined peak annual sales potential of $1.8 billion, the analysts said. RBC raised its price target on Acadia Pharmaceuticals to $38 from $36 and kept its outperform rating. Price: 22.45, Change: +0.98, Percent Change: +4.54